Drug Target Insights
Synopsis: An open access, peer reviewed electronic journal that covers drug treatment targets.
Indexing: 6 major databases. Pubmed indexing for NIH-funded research.
Processing time: Decision in 2 weeks for 90% of papers.
Visibility: Most popular article read 1400+ times.
About this journal
Aims and scope:
Drug Target Insights covers current developments in all areas of the field of clinical therapeutics. The journal has two specific areas of focus:
- On molecular drug targets, including disease-specific proteins, receptors, enzymes, and genes.
- The journal seeks to elucidate the impact of new therapeutic agents on patient acceptability, preference, satisfaction and quality of life.
Drug Target Insights seeks to be the most up-to-date journal for those who need to be informed of the latest and most important developments in the field. The journal seeks to be the most reliable and up-to-date journal in this field by offering rapid and credible pre-production submission processing to authors. By publishing in open-access format, authors are able to communicate with the widest possible group of readers.
Editorial standards and procedures:
Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers. Reviewers are required to provide fair, balanced and constructive reports.
Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair. Appeals are considered by the Editor in Chief or Associate Editor.
Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.
Indexing:
This journal is indexed by the following services:
- Embase
- Google Scholar
- CAS
- DOAJ
- OAIster
SPARC Europe Seal award winner:
This journal has been awarded a SPARC Europe Seal. The Seal is an initiative of SPARC Europe (Scholarly Publishing and Academic Resources Coalition) and the Directory of Open Access Journals (DOAJ) which is awarded to journals applying a Creative Commons CC-BY copyright license and that make journal metadata accessible to DOAJ.
Amongst other important services DOAJ makes metadata OAI-compliant. This in turn enhances the visibility of papers and allows OAI-harvesters to include the details of journal articles in their services. We encourage readers to make use of this valuable resource. The DOAJ search page is available here.
National Institutes of Health Public Access Policy compliant:
As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.
If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf.
Call for papers:
Read the Editor in Chief's latest call for papers here.
Submission types accepted:
Submissions of the following types of manuscripts are accepted:
- Original research articles.
- Reviews: comprehensive, authoritative, descriptions of any subject within the journal's scope. They may cover basic science and clinical reviews, ethics, pro/con debates, and equipment reviews.
- Commentaries: focused and opinionated articles on any subject within the journal's scope. These articles are usually related to a contemporary issue.
- Hypotheses: articles that present an original hypothesis backed solely by previously published results rather than any new evidence. They should outline significant progress in thinking that would also be testable.
- Letters to the Editor: these can be either a re-analysis of a previously published article, or a response to such a re-analysis from the authors of the original publication.
- Methodology articles: these discuss a new experimental method, test or procedure. The article must describe a demonstrable advance on what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value.
- Short reports: brief reports of data from original research.
- Meeting reports: a report pertaining to activity at a meeting or conference Articles published in this journal are immediately available without delay upon publication and enjoy substantial visibility.
All submissions are subject to prompt, objective and fair peer review in compliance with our Fairness in Peer Review Policy. Copyright in published articles remains with the author(s). Authors are continually informed of the progress of their paper and our staff are friendly and responsive.
One author recently wrote: "I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."
Criteria for publication:
Publication is dependent on peer reviewers' judgement of papers. Reviewers are asked to provide thoughtful and unbiased feedback to authors to ensure that the conclusions of papers are valid and manuscripts achieve reasonable standards of scholarliness and intelligibility.
Previous work in the field must be acknowledged and papers should read without unreasonable difficulty. Papers should fit comfortably within the scope of the journal.
Reviewers are asked to act in a fair, objective and constructive manner which maintains quality standards and helps authors to communicate their research. They are instructed that in areas of genuinely novel research issues may be raised which cannot immediately be resolved and that absolutely rigorous validation of data may therefore not be possible.
More information on the role of peer reviewers is available on the information for reviewers page. Where authors consider that reviewers have made recommendations which are unreasonable, unobjective or ill-founded they may appeal them to the Editor in Chief or Associate Editor under our Fairness in Peer Review Policy.
Articles submitted to other journals:
We are willing to consider papers which have been peer reviewed by other journals but not accepted for publication.
Services for authors:
Prior to peer review of your paper we can:
- Have your paper's reference style revised to meet our requirements,
- Have your paper's English revised by specialist English-speaking technical editors.
After peer review of your paper we can:
- Have your paper revised in accordance with peer reviewer's recommendations and have a summary of responses to the reviewers created by our specialist external substantive editors,
- Provide bound reprints of your article in colour or black and white ,
- Provide online-early rapid publication if your paper prior to typesetting.
What other authors have said:
Libertas Academica actively requests, receives and acts upon feedback from authors, readers and editorial boards. Here's what some recent authors have said about us:
"Within a couple of days the reviewers had been procured and the manuscript was out."
"The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I've never had such complete communication with a journal."
"LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought."
Article processing fees:
All submissions to this journal are subject to an article processing fee if they are accepted for publication. Article processing fees are used to fund the processing of your paper and development of the journal. Article processing fees are the only compulsory charge you will face and do not vary according to word count, page count, colour figures or any other factor. There is no additional charge for the author(s) to make any use of their article and no charge to readers to access it.
Full fee waivers are available for authors working in undeveloped nations and partial discounts of 20-50% are available to authors in other nations. Authors must be able to verifiably demonstrate their suitability for a discount or waiver. Availability of waivers and discounts is subject to monthly availability and is given at the publisher's discretion. Waivers and discounts must be applied for prior to submission. Neither are available after submission.
Register as a peer reviewer:
Do you wish to register as a peer reviewer? Or are you already a registered peer reviewer but you need to update your contact details? To register or update your details visit the peer reviewer registration form.
Applicants must be able to demonstrate at least five years of continuous experience in the journal's subject area including at least two in the previous 24 months.
The Editor in Chief has issued a new call for papers. Read it here.
The journal has been accepted for indexing in EBSCO Academic Search Complete.
Recent Advancements in Targeted Delivery of Therapeutic Molecules in Neurodegenerative Disease - Spinocerebellar Ataxia - Opportunities and Challenges
Satya Prakash and Meenakshi Malhotra
Biomedical Technology and Cell Therapy Research Laboratory, Departments of Biomedical Engineering and Physiology Artificial Cells and Organs Research Center Faculty of Medicine McGill University, Montreal, Canada
Abstract
Drug discovery and its methodologies have been very effective in terms of treating cancers and immunological disorders but have not been able to stop genetic diseases as most of the drugs target at the protein level. They merely mitigate the symptoms of the disease. Spinocerebellar ataxia is a neurological genetic disorder that is caused by the formation of an abnormal protein. There have been several reports on ataxic drug development but actual clinical treatment is yet to be achieved. Oligonucleotide therapy called sequence specific siRNA mediated gene silencing has evolved with promising results. This approach emphasizes on suppressing the expression of the diseased gene at mRNA level. However, there is a limitation in delivery of siRNA to the target site. Several methods have been developed over the last decade to enhance the target specific delivery of DNA, siRNA, protein and small drug molecules for therapeutic purpose with less or no side effects. This review discusses the latest upcoming technologies in the field that focus on a number of nonviral nanocarriers for targeted delivery. In this review, we explore the promise and potential of novel therapeutics with interest on ataxia therapy.
Nice review to read that has given a good insight on various isoforms of SCA. However, concepts like BBB have to be addressed with the nanoparticles delivering the drugs. The BBB behaviour of one nanoparticle need not to be the same with another or with other payload. In addition, the potential toxicological impact of such novel drug delivery system is yet to be established. The clinical studies for the nanoparticle based drug delivery system for the CNS system is not fully designed by FDA or the allied CROs. As on today no one has tried to determine the dosage of siRNA for SAD/MAD Phase I trails. Most importantly, the technology to monitor the in vivo drug delivery through these novel drug delivery systems is not sensitive to analyze such nano level drug systems. We still have a long way to go.
Readers of this also read:
- Study of Alkylglycerol Containing Shark Liver Oil: a Physico Chemical Support for Biological Effect?
- Targeted Brain Tumor Treatment: Current Perspectives
- Therapies to Increase ApoA-I and HDL-Cholesterol Levels
- Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy
- The Beta3 499–513 Peptide Region is Required for AlphaIIb/ Beta3 Active Complex Formation and Fibrinogen Binding
- 15/Jan/2009
The Toxicity of a Chemically Synthesized Peptide Derived from Non-Integrin Platelet Collagen Receptors
- 13/Aug/2008
The Target of 5-Lipoxygenase is a Novel Strategy over Human Urological Tumors than the Target of Cyclooxygenase-2
- 13/Jun/2008
Study of Alkylglycerol Containing Shark Liver Oil: a Physico Chemical Support for Biological Effect?
- 28/May/2008
Live Typhoid Vaccine for IBD-Patients—Well Tolerated and with Possible Therapeutic Effect
- 16/May/2008
Memantine: Reality and Potentiality
- 08/May/2008
Recent Advancements in Targeted Delivery of Therapeutic Molecules in Neurodegenerative Disease - Spinocerebellar Ataxia - Opportunities and Challenges
- 02/May/2008
The Beta3 499–513 Peptide Region is Required for AlphaIIb/ Beta3 Active Complex Formation and Fibrinogen Binding
- 28/Apr/2008
Therapies to Increase ApoA-I and HDL-Cholesterol Levels
- 23/Apr/2008
Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy
- 23/Apr/2008
Targeting Insulin-Like Growth Factor-1 Signaling into the Central Nervous System for Promoting Myelin Repair
- 18/Apr/2008
Thrombophilia
- 16/Apr/2008
Evidence of a Novel Gene from Aeromonas hydrophila Encoding a Putative Siderophore Receptor Involved in Bacterial Growth and Survival
- 18/Mar/2008
New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term Quetiapine
- 18/Mar/2008
Targeting Gallium to Cancer Cells through the Folate Receptor
- 01/Mar/2008
Targeted Brain Tumor Treatment: Current Perspectives
- 21/Jan/2008
Cytokine, Chemokine and Immune Activation Pathway Profiles in Celiac Disease: An Immune System Activity Screening by Expression Macroarrays
- 21/Jan/2008
Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases
- 11/Dec/2007
Effects of Ascorbic Acid, Alpha-Tocopherol and Allopurinol on Ischemia-Reperfusion Injury in Rabbit Skeletal Muscle: An Experimental Study
- 11/Dec/2007
Effect of live Salmonella Ty21a in Dextran Sulfate Sodium-induced Colitis
- 05/Nov/2007
Delivery Systems for In Vivo use of Nucleic Acid Drugs
- 14/Oct/2007
Use and Safety of Anthroposophic Medications for Acute Respiratory and Ear Infections: A Prospective Cohort Study
- 17/Sep/2007
Targeting Human Immunodeficiency Virus Type 1 Assembly, Maturation and Budding
- 17/Sep/2007
New Insights into the Understanding of Gastrointestinal Dysmotility
- 17/Sep/2007
Modulation of Visceral Nociception, Inflammation and Gastric Mucosal Injury by Cinnarizine
- 19/Jul/2007
Polymeric Nanoparticles, Nanospheres and Nanocapsules, for Cutaneous Applications
- 11/Jul/2007
Trypanothione Reductase: A Viable Chemotherapeutic Target for Antitrypanosomal and Antileishmanial Drug Design
- 19/Jun/2007
The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
- 15/Jun/2007
The Adaptogens Rhodiola and Schizandra Modify the Response to Immobilization Stress in Rabbits by Suppressing the Increase of Phosphorylated Stress-activated Protein Kinase, Nitric Oxide and Cortisol
- 30/May/2007
Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
- 29/May/2007
Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia
- 18/May/2007
Phospholipase A2 Activates Hemostasis
- 22/Mar/2007
Targeting Receptors, Transporters and Site of Absorption to Improve Oral Drug Delivery
- 06/Mar/2007
Electrocardiographic Findings in Acutely and Chronically T. cruzi-infected Mice Treated by a Phenyl-Substituted Analogue of Furamidine DB569
- 05/Mar/2007
The Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue
- 28/Feb/2007
Modification of Monoaminergic Activity by MAO Inhibitors Influences Methamphetamine Actions
- 27/Feb/2007
Neurogenesis and The Effect of Antidepressants
- 26/Feb/2007
Inhibition of Intrinsic Thrombin Generation
- 25/Feb/2007
Neurogenesis and Alzheimer's Disease
- 24/Feb/2007
Accelerators of Osteogenesis by Recombinant Human Bone Morphogenetic Protein-2
- 21/Feb/2007
Long-term L-Carnitine Administration reduces Erythropoietin Resistance in Chronic Hemodialysis Patients with Thalassemia Minor
- 14/Feb/2007
Cyclophilin and Viruses: Cyclophilin as a Cofactor for Viral Infection and Possible Anti-Viral Target
- 14/Feb/2007
Effect of Ribavirin Alone or Combined with Silymarin on Carbon Tetrachloride Induced Hepatic Damage in Rats
- 14/Feb/2007